揭穿
医学
卵巢癌
外科
化疗
阶段(地层学)
置信区间
上皮性卵巢癌
内科学
癌症
肿瘤科
生物
古生物学
作者
Vasileios Mitsopoulos,Anni Innamaa,Jonathan Lippiatt,Sarah A. Collins,Ioannis Biliatis
出处
期刊:Anticancer Research
[Anticancer Research USA Inc.]
日期:2022-03-28
卷期号:42 (4): 2003-2008
被引量:3
标识
DOI:10.21873/anticanres.15679
摘要
This study aimed to identify differences in the pattern and timing of recurrence in patients with advanced ovarian cancer undergoing primary (PDS) or interval debulking surgery after neoadjuvant chemotherapy (NACT).Data were prospectively collected on 105 patients from June 2016 to March 2020.There were 30 (50%) recurrences in the PDS group compared to 32 (72.7%) in the NACT group (p=0.020). An intra-abdominal relapse was more common in NACT compared to PDS patients (64.4% vs. 38.3%, p=0.008) and a recurrence in two or more sites (NACT: 44.4% vs. PDS: 23.3%, p=0.010). Among completely cytoreduced patients, a pelvic recurrence was more frequent in NACT patients (NACT: 50% vs. 22.4% in PDS, p=0.011). Progression-free survival (PFS) was longer in PDS compared to NACT (27 vs. 16 months, p=0.039).NACT patients experienced an unfavorable distribution and timing of recurrent disease compared to patient who underwent PDS.
科研通智能强力驱动
Strongly Powered by AbleSci AI